30 Aug MORE Act vs. Schedule III: What’s the real difference—and what actually helps?
The newly reintroduced MORE Act would remove cannabis from the Controlled Substances Act (CSA) and pair that with record-clearing and equity programs. Trump’s floated move would reschedule cannabis to Schedule III, easing taxes and research limits but not legalizing state markets or ending criminalization. They solve different problems—one is full federal legalization; the other is a partial, administrative fix.
What just happened?
- MORE Act reintroduced (Aug 29, 2025). House sponsors led by Rep. Jerry Nadler re-filed the Marijuana Opportunity Reinvestment and Expungement Act, which would deschedule cannabis and create justice and reinvestment programs.
- Schedule III talk heats up (Aug 8–9, 2025). Multiple outlets reported that President Trump is considering moving cannabis from Schedule I to Schedule III. That would be a rescheduling—not legalization.
Quick definitions
- Deschedule (MORE Act): Cannabis is removed from the CSA entirely—treated more like alcohol at the federal level. Congress must pass a law to do this.
- Reschedule to Schedule III: Cannabis stays on the CSA but in a lower category with “accepted medical use.” Agencies can do this through rulemaking. It loosens some rules but keeps federal control and criminal penalties in many contexts.
Side-by-side snapshot
Issue |
MORE Act (Deschedule) |
Schedule III (Reschedule) |
|---|---|---|
Federal legality of adult-use |
Ends federal prohibition; states decide their own systems without CSA conflict | Still federally illegal outside FDA-approved drugs; state programs remain in conflict with CSA |
Criminal justice & records |
Expungements/resentencing; reinvestment in communities harmed by the drug war | No automatic record relief; criminal penalties remain for non-compliant activity |
State-licensed businesses |
Removes CSA risk; opens path to interstate commerce (subject to new federal rules) | State markets still technically illegal federally, but day-to-day risk may remain similar to today |
Taxes (IRC 280E) |
280E no longer applies because cannabis isn’t a controlled substance | 280E relief arrives immediately once Schedule III takes effect |
Banking & finance |
Much easier (federal illegality removed) | Incremental improvement; some risk remains since cannabis stays controlled |
R&D / FDA medicines |
R&D easier post-descheduling; new federal framework needed | Major boost to research access and potential FDA-approved cannabis medicines |
Speed & odds |
Needs Congress; historically tough | Could move via executive branch; faster if prioritized |
Sources for the key points above: MORE Act scope and equity elements; 280E relief at Schedule III; and the fact that Schedule III does not legalize state markets.
The MORE Act: Pros & cons
Pros
- Ends federal prohibition by removing cannabis from the CSA—resolving the core federal/state conflict.
- Justice & equity measures (expungement, resentencing, and community reinvestment) are built in, not bolted on.
- Banking, insurance, and capital become straightforward because the product is no longer a controlled substance.
Cons
- Political difficulty: It must pass both chambers; past versions cleared the House but stalled in the Senate.
- New federal framework required: Congress and agencies would still need to set interstate rules, product standards, labeling, and safety regs—work that takes time.
Schedule III: Pros & cons
Pros
- Immediate 280E relief: State-licensed operators can deduct ordinary business expenses—game-changing cash-flow relief for distressed retailers and cultivators.
- Research acceleration: Schedule III status recognizes medical use, easing approvals for studies and enabling a clearer FDA pathway for cannabis-based medicines.
- Faster to implement: Can happen via administrative rulemaking if the White House truly prioritizes it (and withstands court challenges). Recent reporting says it’s under active consideration.
Cons
- Not legalization: State adult-use markets remain in technical violation of federal law; criminal penalties persist for non-compliant conduct and interstate trafficking.
- FDA/Big Pharma dynamics: Schedule III could invite more pharma-style products without resolving existing state market conflicts—creating a two-track system (prescription cannabis vs. state retail).
- Banking still muddy: Some risk and compliance hesitation may persist because cannabis remains a controlled substance.
Which helps consumers and small businesses more?
- Short term: Schedule III provides immediate tax relief (goodbye 280E) and makes research easier. That could stabilize many operators and improve product innovation quickly.
- Long term: Only descheduling (MORE Act) fully normalizes the industry, removes criminal penalties at the federal level, harmonizes banking/insurance, and squarely addresses expungement and reinvestment.
Timelines and likelihood
- MORE Act: Reintroduced on August 29, 2025—but faces the same political headwinds that stalled earlier versions. Expect hearings and headlines; passage remains uncertain without broad bipartisan buy-in.
- Schedule III: Reports indicate the White House is actively weighing it now (early August 2025). If pursued, rulemaking could move faster than legislation, though litigation is likely.
Bottom line (and why it matters in Florida)
If you want true legalization, clean banking, and justice built into the policy, the MORE Act is the vehicle. If you need near-term relief—especially from crushing taxes—and a smoother path for medical research, Schedule III delivers tangible benefits sooner but doesn’t end prohibition. In practice, the smartest path for the industry and consumers might be both: take the immediate wins of Schedule III while pushing Congress to finish the job with comprehensive descheduling and equity.
No Comments